Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Neutron-Activated vs Fission-Produced 99mTc-MDP for Bone Scans
NCT03002454Phase 3Terminated
- Sponsor
- University of Manitoba
- Start
- Aug 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of technetium-99m-methylene diphosphonate in bone cancer, sponsored by University of Manitoba. Primary endpoint: Diagnostic Efficacy of Technetium (99mTc) Medronate Injection Prepared With 99mTc Derived From Neutron-activation Produced 99Mo Imaging Sensitivity Versus 99mTc Derived From Fission-produced 99Mo… at 60 days. Started Aug 2016; status: terminated.
02
Drugs
technetium-99m-methylene diphosphonate
03
Conditions
bone cancer
Beyond the preview
Go deeper on NCT03002454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002454.